Long non-coding RNAs (lncRNAs) perform distinct biological functions by regulating gene expression through various molecular mechanisms under normal physiological and pathological conditions. However, the function of the stomach cancer-associated transcript-3 (STCAT3) lncRNA, including its prognostic significance and role as a binding protein in gastric cancer (GC), remain unclear. In the present study, 56 potential binding proteins of STCAT3 were screened using through mass spectrometry and bioinformatics analysis. Among these, dermcidin, GAPDH, annexin, calmodulin-like protein, cathepsin-D and suprabasin were demonstrated to be candidate binding proteins using a literature search. RNA-protein interaction prediction was used to confirm these six proteins. Finally, dermcidin was identified as the binding protein of STCAT3 by comparing the mRNA and protein levels of the candidate genes and their correlations with STCAT3 in plasmid-transfected BGC-823 GC cell lines, as well as by validating the interplay between dermcidin and STCAT3 in other GC cell lines. Immunohistochemical analysis of tissues from 98 patients with GC further confirmed the interaction between dermcidin and STCAT3. The results of the present study also revealed that STCAT3 and dermcidin and independent predictors of overall survival in patients with GC. Furthermore STCAT3 and dermcidin are positively correlated with lymph node metastasis and tumor/node/metastasis score. In summary, the present study suggests that dermcidin is a novel binding protein of lncRNA STCAT3, which serves an important role in the progress and clinical outcome of GC.
Introduction
Gastric cancer (GC) is one of the most common malignant tumors and a major cause of cancer-associated mortality worldwide (1) . Early diagnosis and effective treatment for GC are difficult to achieve as the underlying molecular mechanisms are unclear (2) . As such, increasing our understanding of the mechanisms responsible for GC is crucial to allow for early diagnosis, effective therapy and survival prediction.
Long noncoding RNAs (lncRNAs) are RNAs >200 bp in length that are not directly translated into protein (3, 4) . LncRNAs account for only 4-9% of the mammalian transcriptome (5) ; however, a number of reports indicate that lncRNAs serve key roles in gene expression, gene imprinting, DNA recombination, chromatin modification, cell cycle regulation and encoding peptides (6) (7) (8) (9) . It has been reported that lncRNAs interact with genomic DNA and chromatin in the following ways: i) Forming a DNA-RNA heteroduplex by binding to regions of single-stranded DNA; ii) forming DNA-DNA-RNA triplexes by Hoogsteen or reverse Hoogsteen base pairing; iii) tethering to chromatin through association with RNA polymerase II and thereby acting as allele-specific signatures for a specific locus; iv) indirectly binding to chromatin by binding to chromatin-associated proteins or transcription factors; and v) directly forming sense chromatin structures (10) . LncRNA is able to exert a wide range of regulatory functions, including on cell growth, apoptosis, migration, invasion and autophagy (11) .
A previous study by our research group revealed that lncRNA STCAT3 overexpression promoted the proliferation and invasion of GC cells and that STCAT3 interference significantly inhibited GC (12) . However, the potential pathological mechanisms of STCAT3 and its prognostic significance in patients with GC remain uncertain. The aim of the present study was to screen and identify proteins that interact with STCAT3 by using RNA pull-down technology and mass spectrometry. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blotting were used to measure mRNA and protein expression, respectively. RNA binding protein immunoprecipitation (RIP) experiments were also performed. The prognostic value of STCAT3 and Dermcidin as a novel binding protein of lncRNA STCAT3 and its effect on prognosis in gastric cancer its binding protein in GC was evaluated using univariate Cox proportional hazards regression models.
Materials and methods
Patients and clinical samples. -TAA TAC GAC TCA CTA TAG GGG TCT ATT TGA TTC TTC  TCT C-3' and reverse 5'-GGA GCT GAA AAA CAC AGC-3';  antisense chain, forward 5'-TAA TAC GAC TCA CTA TAG GGG  GAG CTG AAA AAC ACA GCA T-3' and reverse 5'-GTC TAT  TTG ATT CTT CTC TC-3 (13) . Each RT-qPCR experiment was performed in triplicate. Tumor tissues were assigned to the high expression group when STCAT3 expression was two fold higher compared with adjacent normal tissues.
Western blotting. Western blotting was performed to assess the expression of dermcidin, GAPDH, calmodulin, cathepsin D, suprabasin, Annexin A2 and β-actin proteins as described previously (14) . Briefly, cells were rapidly homogenized in a buffer containing 10 µg/ml leupeptin, 1% Triton X-100, 10% sodium dodecyl sulfate (SDS), 1 m Tris-HCl (pH 7.5), 0.5% sodium deoxycholate, 10 µg/ml aprotinin, 1% Nonidet™ P-40, 1 mm phenylmethylsulfonyl fluoride and 0.5 m ethylenediaminetetraacetic acid, following which they were centrifuged at 10,000 x g for 30 min at 4˚C and collect the supernatant. Protein concentrations were determined using a Bio-Rad protein assay (Bio-Rad Laboratories, Inc., Hercules, CA, uSA). Equal amounts of protein (40 µg/lane) were separated by 15% SDS-PAGE and transferred to polyvinylidene difluoride membranes. The membranes were blocked with 5% dried skimmed milk in Tris-buffered saline and Tween-20 containing 0.05% Tween-20, 20 mm Tris, and 150 mm NaCl for 2 h at room temperature. membranes were incubated at 4˚C overnight with the following monoclonal primary antibodies: Rabbit anti-dermcidin (cat. no. ab52138), rabbit anti-GAPDH (cat. no. ab181602), rabbit anti-calmodulin (cat. no. ab45689), rabbit anti-cathepsin D (cat. no. ab75852), rabbit anti-suprabasin (cat. no. ab232771) and rabbit anti-Annexin A2 (cat. no. ab178677; all 1:2,000; all Abcam). mouse anti-β-actin (cat. no. ab8226; 1:2,000; Abcam) monoclonal antibody was used as an internal control. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG H&L (1:10,000; cat. no. ab97051; Abcam) and rabbit anti-mouse IgG H&L cat. no. ab6728; 1:5,000; Abcam) were used as secondary antibodies for 2 h at room temperature. The proteins were visualized using an enhanced chemiluminescent detection system (GE Healthcare Life Sciences, Little Chalfont, uK), according to the manufacturer's protocol. Following chemiluminescence, bands were exposed to X-ray films (Kodak, Rochester, NY, uSA) and ImageJ 1.37 software (National Institutes of Health, Bethesda, mD, uSA) was used for grey value analysis. Relative amounts of proteins were quantified by absorbance analysis and normalized to β-actin. The experiments were repeated three times.
Immunohistochemistry. Tumor and adjacent normal tissues were fixed in 10% buffered formalin for 24 h at room temperature, embedded in paraffin and cut into sections (4 µm). The sections were deparaffinized in xylene, rehydrated in graded ethanol solutions and treated with 0.1% hydrogen peroxide in methanol for 20 min to remove endogenous peroxidase activity. Antigen retrieval was performed by microwaving the sections immersed in 10 mm citric acid buffer for 10 min, followed by 1-h incubation at room temperature. To block non-specific protein binding, sections were incubated with 5% bovine serum albumin (cat. no. LLBB-1000-01; Surmodics, Inc., Eden Prairie, USA) for 10 min at 37˚C. Sections were incubated at room temperature for 1 h with monoclonal antibody against dermcidin (cat. no. ab52138; 1:50; Abcam) and again overnight at 4˚C. Sections were washed with PBS and incubated with HRP-conjugated polyclonal goat anti-rabbit IgG (H&L) biotin secondary antibodies (cat. no. E030110-01; 1:500; EarthOx, LLC, San Francisco, CA, uSA) for 1 h at room temperature, followed by 0.1% hydrogen peroxide and 0.6 mm 3,3'-diaminobenzidine (DAB) in PBS for 8 min at room temperature. Omission of the primary antibody served as a negative control. All sections were counterstained with hematoxylin for 2 min at room temperature and examined using a light microscope (BX51; Olympus Corporation, Tokyo, Japan; magnification, x100 and x400). Two consultant pathologists assessed slides in a blinded fashion.
Staining was evaluated as previously described (14) .
Statistical analysis. All statistical analyses were performed using SPSS 17.0 (SPSS, Inc., Chicago, IL, uSA), and graphs were generated using GraphPad Prism software version 5.0 (GraphPad Software, Inc., La Jolla, CA, uSA). Differences between groups were analyzed using Student's t-test, one-way analysis of variance, the χ 2 test, Spearman's rank correlation coefficient or Pearson's correlation coefficient, as appropriate. Student-Newman-Keuls post hoc test was performed following ANOVA. Variables associated with overall survival (OS) and time to recurrence (TTR) were assessed using univariate Cox proportional hazard regression models. Kaplan-meier plots (log-rank tests) were used to describe OS and TTR. P<0.05 was considered to indicate a statistically significant difference.
Results
STCAT3 is highly expressed in GC tissues. The expression of STCAT3 was detected in 98 paired GC tissues and adjacent normal tissues using RT-qPCR normalized to β-actin. STCAT3 expression in GC tissues was significantly higher compared with in the adjacent normal gastric tissues (P<0.05; Fig. 1A ). The expression of STCAT3 varied dramatically between GC cell lines, however it was upregulated in all GC cell lines compared with the normal gastric mucosa cell line GES-1 (all P<0.05). In particular, STCAT3 expression was much higher in BGC-823, mKN-45 and SGC-7901 compared with the GES-1 cell line (Fig. 1B) .
STCAT3 is and is associated with advanced clinical stage and poor survival. The clinical features of patients with GC are presented in Table III . STCAT3 expression in GC tissues was positively correlated with TNm stage and lymph node metastasis; patients with GC of TNm stages III/IV had significantly higher STCAT3 expression compared with those with GC at stages I/II (P<0.05; Fig. 1C ). Furthermore, patients with positive lymph node metastasis had significantly higher STCAT3 expression compared with patients with no lymph node metastasis (P<0.05; Fig. 1D ). Other clinical characteristics, including histological grade, invasion depth, sex and age, were not correlated with STCAT3 expression. Kaplan-meier analysis and log-rank test were performed to determine the association between the STCAT3 expression in GC tissues and patient prognosis. The median time until postoperative recurrence in the patients with high STCAT3 expression levels was significantly shorter compared with the low STCAT3 group (P<0.05; Fig. 1D ). Furthermore, the median survival time in the low STCAT3 expression group was significantly longer compared with the high expression group (P<0.05; Fig. 1E ).
Screening and identification of dermcidin as a novel binding protein of lncRNA STCAT3. STCAT3 was used to capture its interacting protein using the BGC-823 cell line. A notable difference was observed between the sense and antisense strands of STCAT3 following electrophoresis silver staining. The protein of band 2 was decomposed and analyzed using mass spectrometry ( Fig. 2A) . Species database retrieval and bioinformatics analysis were performed and 56 proteins were different regarding statistics or function (data not shown).
mounting studies have reported that dermcidin (15-17), GAPDH (18) , annexin (19, 20) , calmodulin-like protein (21, 22) , cathepsin-D (23) and suprabasin (24) are associated with malignant tumors. Based on this, RNA-protein interaction prediction was used to assess whether these proteins were binding candidates for STCAT3. The interaction probabilities for all proteins were >0.5, suggesting that these proteins may be candidate binding proteins for STCAT3. To identify the binding protein for STCAT3, the plasmid vectors STCAT3-pCDNA3.1, pCDNA3.1, sh-STCAT3 and sh-NC were transfected into BGC-823 cells. STCAT3 expression in the STCAT3-pCDNA3.1 group was significantly higher compared with the pCDNA3.1 group (P<0.001; Fig. 2B ). In contrast, STCAT3 expression in the sh-STCAT3 group was decreased compared with the sh-NC group (P<0.001; Fig. 2B ). RT-qPCR was used to measure the mRNA expression of the potential binding proteins in the sh-STCAT3 and sh-NC groups. Dermcidin, suprabasin and calmodulin-like proteins were significantly downregulated in the sh-STCAT3 group compared with the sh-NC group (P<0.05; Fig. 2C ). However, the expression of annexin, cathepsin-D and GAPDH was not significantly different between groups. Furthermore, dermcidin, suprabasin and calmodulin-like protein expression was positively correlated with lncRNA STCAT3 expression (Pearson r=0.985, 0.932 and 0.941; P<0.05), suggesting that they were candidate STCAT3 binding proteins.
In contrast, the results of western blotting (Fig. 2D ) revealed that dermcidin, annexin and cathepsin D protein expression in the sh-STCAT3 group was significantly lower compared with the sh-NC group (P<0.05; Fig. 2E ). These protein levels were positively correlated with STCAT3 expression (Pearson r=0.967, 0.868, 0.971; P<0.05). Suprabasin protein expression was significantly increased in the sh-STCAT3 group compared with the sh-NC group and was negatively correlated with STCAT3 (Pearson r=-0.951; P<0.05; Fig. 2E ). As such, in terms of protein expression, dermcidin, annexin and cathepsin D were identified as potential binding proteins of STCAT3. Based on these above results, dermcidin was identified as a novel binding protein that can interact with the lncRNA STCAT3.
Validation of dermcidin as a novel binding protein of lncRNA STCAT3. To confirm dermcidin as a novel binding protein of STCAT3, dermcidin expression was measured in a number of GC cell lines. RT-qPCR and western blotting revealed that dermcidin expression was significantly increased in the STCAT3-pCDNA3.1 group compared with the pCDNA3.1 group (P<0.001; Fig. 3A-C) . However, dermcidin expression was significantly lower in the sh-STCAT3 group compared with the sh-NC group (P<0.01; Fig. 3A-C) . To confirm direct binding between lncRNA STCAT3 and dermcidin, RIP-qPCR was performed to measure STCAT3 expression in the STCAT3-pCDNA3.1 and pCDNA3.1 groups. LncRNA STCAT3 co-immunoprecipitated by the protein dermcidin was significantly higher in the STCAT3-pCDNA3.1 group compared with the pCDNA3.1 group (P<0.001; Fig. 3D ). These data suggest that dermcidin is the direct-binding protein of lncRNA STCAT3.
Dermcidin expression is positively correlated with STCAT3 and poor survival in patients with GC. The expression of dermcidin was measured in GC tissues from 98 patients with GC using immunohistochemistry. Positive staining for dermcidin was localized to the cell nucleus and cytoplasm in GC tissues (Fig. 4A-D) . The rate of dermcidin expression was 63.26% (62/98) in GC tissues, whereas it was weakly expressed in normal adjacent tissues. Dermcidin expression was also demonstrated to be significantly associated with clinical TNm stage, tumor differentiation and lymph node metastasis (all P<0.05; Table IV) .
Spearman's rank correlation between STCAT3 mRNA and dermcidin protein expressions in human GC tissue samples was calculated and a positive correlation was observed between STCAT3 and dermcidin protein expression in GC tissues (r=0.5270; P<0.001; Table V ). To investigate the association between dermcidin expression and GC prognosis, Kaplan-meier analysis and the log-rank test were performed. The median time until postoperative recurrence and median survival duration were significant higher in the low dermcidin expression group compared with the high expression group (P<0.001; Fig. 4E and F) , indicating that dermcidin overexpression is a predictor of poor prognosis in patients with GC.
To confirm the prognostic value of STCAT3 and dermcidin expression in patients with GC, univariate and multivariate survival analyses (Cox proportional hazards regression model) were performed. The univariate analysis included ten prognostic factors: Age, sex, tumor size, invasion depth, TNm stage, differentiation grade, lymph node metastasis, STCAT3 expression and dermcidin expression. The results revealed that STCAT3 and dermcidin expression are independent predictors of OS (P<0.05) and TNm stage (P=0.014) in patients with GC (Table VI) .
Discussion
Despite advances in surgery, chemotherapy and targeted molecular therapies, GC remains a leading contributor to cancer-associated mortality worldwide (1, 25) . Developing a better understanding of the molecular mechanisms underlying the development and progression of GC may allow for early diagnostic and treatment methods to be developed, improving the, overall prognosis.
A number of studies have reported that lncRNAs serve vital roles in a range of human diseases, including GC and other cancers (26, 27) , functioning as potential oncogenes or tumor suppressors (28) (29) (30) (31) . For example, HOTAIR expression is upregulated in GC tissues and is an independent predictor of poor prognosis and HOTAIR knockdown in GC cells suppresses the migration and invasion of GC cells; this suggests that HOTAIR functions as a novel oncogene in GC (32, 33) . LncRNA gastric carcinoma high expressed transcript 1 overexpression is associated with gastric tumor growth and invasion, promoting the proliferation of GC cells by enhancing the interaction between c-myc mRNA and insulin-like growth factor 2 binding protein 1 (34) . Additionally, GHET1 overexpression promotes the development of multidrug resistance, which is associated the expressions B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X, mDR, and multidrug resistance-associated protein 1 genes in GC cells (35) . LncRNA urothelial cancer-associated 1 increases the metastatic ability of GC cells by regulating GRK2 protein stability via Cbl-c-mediated GRK2 ubiquitination and degradation (36) .
The authors of the present study have previously reported that novel lncRNA STCAT3 was highly expressed in GC tissues, was able to promote the proliferation, migration and invasion of GC cells in vitro and promote the growth of transplanted tumors in vivo (12) . The results of the present study support these findings. It was also demonstrated that STCAT3 expression was significantly upregulated in GC compared with paired adjacent tissues. STCAT3 upregulation in patients with GC was positively correlated with advanced TNm stage and lymph node metastasis. Furthermore, high STCAT3 expression in GC tissues was associated with poor prognosis. These results suggest that STCAT3 may function as an oncogene in GC.
To further identify the molecular mechanisms and binding partners of STCAT3, mass spectrometry was performed in BGC-823 cells followed by an RNA pull-down assay. The results demonstrated that STCAT3 interacts with dermcidin, which was further verified by RT-qPCR and western blotting. The results were also verified using an RIP-qPCR assay and it was demonstrated that STCAT3 could be enriched in dermcidin precipitates, indicating that dermcidin is a novel binding protein of lncRNA STCAT3.
A number of studies have reported that dermcidin serves a role in the carcinogenesis of a number of tumor types, including lung cancer (16, 37) , melanoma (17, 38) , breast cancer (39) (40) (41) , hepatocellular carcinoma (HCC) (42, 43) , prostatic carcinoma (44) and pancreatic cancer (15) . Dermcidin may also affect breast cancer development through the ERBB signaling pathway (41) .
Immunohistochemical results revealed that, compared with pair-matched normal gastric tissues, dermcidin was overexpressed in GC. Furthermore, the dermcidin expression was significantly correlated with clinical TNM stage, tumor differentiation and lymph node metastasis. Importantly, a positive correlation was observed between the expression of STCAT3 and dermcidin in GC tissues. The median time until postoperative recurrence was increased in the low dermcidin expression group, as was the OS duration. These results indicate that dermcidin overexpression is a predictor of poor prognosis in patients with GC. The present study is not without limitations. Although it was determined that dermcidin is the interaction protein of lncRNA STAT3, the mechanism that leads to the formation of lncRNA STCAT3 remain to be elucidated. Furthermore, the sample size used in the present study was small. These limitations should be addressed in future studies.
In summary, the results of the present study indicate that dermcidin is a novel binding protein of lncRNA STCTA3, which serves an important role in cancer progression and patient clinical outcomes in GC. The results of the present study provide a theoretical basis for follow-up studies investigating the regulatory mechanism of lncRNA STCAT3 in the occurrence and development of GC and its potential as a molecular therapeutic target.
